TP53 and prostate carcinoma: Studies have shown that the WEE1 inhibitor Adavosertib (AZD1775) has a significant synthetic lethal effect on tumors carrying p53 mutations, and the drug has been shown to be effective against a wide range of TP53-mutated cancers including colorectal [88], gallbladder [89], breast [90], pancreatic [91], and prostate cancers [92].